Sun Pharmaceutical Industries (BOM:524715, NSE:SUNPHARMA) reported Phase 2 trial results for SCD-044 in moderate to severe psoriasis and atopic dermatitis, according to a Tuesday filing on the local bourse.
Neither trial met the primary endpoint of 75% improvement by Week 16.
No major safety concerns were observed. The company is discontinuing SCD-044's development and will consider next steps with its partner.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。